All In Biotech

Drug Trial Radar · NCT07850609

A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)

Protocol Title: A Phase 2 Open-label Study to Evaluate the Safety and Pharmacokinetics of MK-8527 Oral Once-monthly in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of HIV-1 Exposure

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Oct 27, 2026

Primary completion

Dec 2, 2027

Study completion Dec 2, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to learn about the safety of alimatravir (MK-8527) in transgender and gender-diverse people and if they tolerate it.

Conditions

  • HIV

Interventions

  • AlimatravirDrug

    11 mg tablets taken orally once monthly (qm) for a total of 3 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 4 months
  2. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 2 months

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Bridge HIV - San Francisco Department of Public Health ( Site 0002)

    San Francisco, California · Recruiting

  • Whitman-Walker Institute ( Site 0008)

    Washington D.C., District of Columbia · Recruiting

  • Fenway Health ( Site 0004)

    Boston, Massachusetts · Recruiting

  • Mazzoni Center ( Site 0010)

    Philadelphia, Pennsylvania · Recruiting

  • Maple Leaf Research ( Site 0102)

    Toronto, Ontario, Canada · Recruiting

  • Clinique de médecine Urbaine du Quartier Latin ( Site 0101)

    Montreal, Quebec, Canada · Recruiting

  • Gestion clinique médicale l'Actuel ( Site 0100)

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.